AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3086% above fair value
$286.00−2.84 (-0.98%)
Close on Nov 3, 2026Market cap $505.40BP/E 80.8Yield 2.33%
AbbVie OPEB Interest Cost: $44M in FY2025, up 7.3% from a year earlier. That is the highest of the 11 years on record here.
Latest, FY2025
44
Period ended Dec 31, 2025
Change on a year earlier
+7.3%
41 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Post-Employment Benefits Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | OPEB Interest Cost ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 44 | +7.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 41 | +10.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 37 | +60.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 23 | +21.1% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 19 | -44.1% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 34 | +17.2% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 29 | +16.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 25 | +4.2% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 24 | 0.0% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 24 | +4.3% | Form 10-K (filed 2019-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 23 | – | Form 10-K (filed 2018-02-16) ↗ |
Cite this data
StockData. (2026). AbbVie OPEB Interest Cost ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/db-opeb-int-cost
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?